Bright Drug Industries Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 04-07-2024
- Paid Up Capital ₹ 3.69 M
as on 04-07-2024
- Company Age 37 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.50 Cr
as on 04-07-2024
- Revenue %
(FY 2018)
- Profit 96.62%
(FY 2018)
- Ebitda 95.17%
(FY 2018)
- Net Worth -0.57%
(FY 2018)
- Total Assets 0.71%
(FY 2018)
About Bright Drug Industries
The Corporate was formerly known as Bright Drug Industries Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.69 M.
The company has closed loans amounting to ₹1.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajnish Tripathi, Manoj Garg, and Ritesh Sharma serve as directors at the Company.
- CIN/LLPIN
U24231MP1987PTC004182
- Company No.
004182
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 1987
- Date of AGM
08 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bright Drug Industries?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajnish Tripathi  | Director | 02-Sep-2017 | Current |
| Manoj Garg | Director | 01-Sep-2008 | Current |
| Ritesh Sharma | Director | 30-Sep-2004 | Current |
Financial Performance and Corporate Structure Insights of Bright Drug Industries.
Bright Drug Industries Private Limited, for the financial year ended 2018, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 96.62% increase in profit. The company's net worth dipped by a decrease of 0.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bright Drug Industries?
In 2018, Bright Drug Industries had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Db Infomedia Private LimitedActive 9 years 10 monthsRajnish Tripathi and Manoj Garg are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Central Bank Of India Creation Date: 17 Oct 2006 | ₹1.00 Cr | Satisfied |
Central Bank Of India Creation Date: 17 Oct 2006 | ₹5.00 M | Satisfied |
How Many Employees Work at Bright Drug Industries?
Unlock and access historical data on people associated with Bright Drug Industries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bright Drug Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bright Drug Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
